The treatment landscape for COVID-19 continues to evolve rapidly. Despite the availability of vaccines in the markets under study, ongoing research focuses on decreasing viral loads and improving outcomes for nonhospitalized SARS-CoV-2 patients. While multiple therapies have been approved for the treatment of COVID-19 in the markets under study, most notably Pfizer’s Paxlovid (ritonavir/nirmatrelvir), Gilead’s Veklury (remdesivir), and Merck’s molnupiravir, treatment guidelines in these regions and/or available clinical evidence do not always support the use of all available drugs. Nevertheless, given the high burden of this disease to healthcare systems worldwide, such treatments may be used to address the high unmet need in nonhospitalized settings. Numerous drugs with diverse mechanisms of action are in clinical development for nonhospitalized COVID-19 patients, many of which are expected to launch in the next couple of years. The greater availability of treatment options will continue to transform the treatment landscape and help address the existing unmet need.
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
KEY COMPANIES COVERED
Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer, Regeneron, Sanofi
KEY DRUGS COVERED
Paxlovid (nirmatrelvir/ritonavir), Molnupiravir, Xevudy (sotrovimab), Veklury (remdesivir), REGN-COV2 (casirivimab/imdevimab), LY-CoV555 and LY-CoV016, and other Phase III assets.
United States, France, Germany, United Kingdom, Japan
12 KOL interviews in March 2022